Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H19N3.ClH |
| Molecular Weight | 301.814 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]12CN(C)CCN1C3=C(CC4=C2C=CC=C4)C=CC=N3
InChI
InChIKey=SISMRXGXKXMBKT-PKLMIRHRSA-N
InChI=1S/C17H19N3.ClH/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20;/h2-8,16H,9-12H2,1H3;1H/t16-;/m1./s1
Esmirtazapine (S-(+)mirtazapine or ORG-50081) is an enantiomer of mirtazapine (REMERON®), a high-affinity antagonist at 5-HT2/5-HT3 and H1 receptors, used in the treatment of depression. Esmirtazapine has a shorter plasma half-life than the R(−) enantiomer. Esmirtazapine is preferentially metabolized into an 8-hydroxy glucuronide. Organon was developing esmirtazapine for the treatment of hot flushes (vasomotor symptoms) associated with the menopause and insomnia.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mirtazepine overdose and miosis. | 2003 |
|
| Acute zonisamide overdose: a death revisited. | 2003 Jun |
|
| Behavioral disturbances in dementia. | 2003 Mar |
|
| Compliance: the impact of adverse events and tolerability on the physician's treatment decisions. | 2003 Sep |
|
| Hypertensive urgency with clonidine and mirtazepine. | 2004 Sep-Oct |
|
| Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. | 2005 Dec |
|
| Antidepressants and seizures: emphasis on newer agents and clinical implications. | 2005 Dec |
|
| Evidence of cost-effective treatments for depression: a systematic review. | 2005 Jan |
|
| Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. | 2005 Mar |
|
| Mirtazepine for MDMA-induced depression. | 2005 May-Jun |
|
| Chiral resolution and binding study of 1,3,4,14b-tetrahydro-2,10-dimethyl-2H,10H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzotriazepine (10-methyl-10-azaaptazepine) and 2-methyl-1,3,4,14b-tetrahydro-2H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzothiadiazepine 10,10-dioxide (tiaaptazepine). | 2005 Nov-Dec |
|
| Improvement in cognitive and psychosocial functioning and self image among adolescent inpatient suicide attempters. | 2006 Dec 29 |
|
| Post-traumatic stress disorder. | 2007 Aug 1 |
|
| In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
| Essential tremor. | 2007 May 1 |
|
| Pharmacological management of panic disorder. | 2008 Feb |
|
| Neuropharmacology. | 2008 Oct |
|
| A new paradigm for the prediction of antidepressant treatment response. | 2009 |
|
| Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. | 2009 Apr |
|
| Brain potentials of conflict and error-likelihood following errorful and errorless learning in obsessive-compulsive disorder. | 2009 Aug 12 |
|
| Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. | 2009 Aug 7 |
|
| Management of difficult urticaria. | 2009 Jul |
|
| Extreme thermal sensitivity and pain-induced sensitization in a fibromyalgia patient. | 2010 |
|
| 3D-QSAR design of new escitalopram derivatives for the treatment of major depressive disorders. | 2010 Apr-Jun |
|
| Behavioral and developmental changes in rats with prenatal exposure of mirtazapine. | 2010 Jul-Sep |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
71576069
Created by
admin on Sat Dec 16 08:36:35 GMT 2023 , Edited by admin on Sat Dec 16 08:36:35 GMT 2023
|
PRIMARY | |||
|
1448014-35-4
Created by
admin on Sat Dec 16 08:36:35 GMT 2023 , Edited by admin on Sat Dec 16 08:36:35 GMT 2023
|
PRIMARY | |||
|
J12BQ47O1N
Created by
admin on Sat Dec 16 08:36:35 GMT 2023 , Edited by admin on Sat Dec 16 08:36:35 GMT 2023
|
PRIMARY | |||
|
DBSALT002352
Created by
admin on Sat Dec 16 08:36:35 GMT 2023 , Edited by admin on Sat Dec 16 08:36:35 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
